U.S. patent application number 14/822252 was filed with the patent office on 2016-01-07 for oxidated derivatives of triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments.
The applicant listed for this patent is SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.p.A.. Invention is credited to Walter CABRI, Patrizia MINETTI, Giovanni PIERSANTI, Giorgio TARZIA.
Application Number | 20160002244 14/822252 |
Document ID | / |
Family ID | 40941572 |
Filed Date | 2016-01-07 |
United States Patent
Application |
20160002244 |
Kind Code |
A1 |
CABRI; Walter ; et
al. |
January 7, 2016 |
OXIDATED DERIVATIVES OF TRIAZOLYLPURINES USEFUL AS LIGANDS OF THE
ADENOSINE A2A RECEPTOR AND THEIR USE AS MEDICAMENTS
Abstract
The present invention relates to new triazolyl purine
derivatives of formula (I), processes for their preparation, and to
pharmaceutical compositions containing them for the treatment of
neurological disorders or cerebral ischaemia for which inhibition
of adenosine A2A receptor will result at improving the health state
of a patient.
Inventors: |
CABRI; Walter; (Rozzano
(MI), IT) ; MINETTI; Patrizia; (Rome, IT) ;
PIERSANTI; Giovanni; (Urbino (PU), IT) ; TARZIA;
Giorgio; (Petriano (PU), IT) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.p.A. |
ROME |
|
IT |
|
|
Family ID: |
40941572 |
Appl. No.: |
14/822252 |
Filed: |
August 10, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13257750 |
Nov 14, 2011 |
9133197 |
|
|
PCT/EP2010/053554 |
Mar 18, 2010 |
|
|
|
14822252 |
|
|
|
|
Current U.S.
Class: |
514/263.2 ;
544/277 |
Current CPC
Class: |
A61P 3/00 20180101; C07D
473/34 20130101; A61P 25/16 20180101; A61P 43/00 20180101; A61P
25/14 20180101; A61P 25/28 20180101; A61P 25/00 20180101; A61K
31/198 20130101; A61K 31/52 20130101 |
International
Class: |
C07D 473/34 20060101
C07D473/34; A61K 31/198 20060101 A61K031/198; A61K 31/52 20060101
A61K031/52 |
Foreign Application Data
Date |
Code |
Application Number |
Mar 20, 2009 |
EP |
09155690.2 |
Claims
1-15. (canceled)
16. A compound having the general formula I ##STR00008## R.sup.1 is
C.sub.1-C.sub.6 linear or branched alkyl; R.sup.2 is a group of
formula:
R.sup.9--(CHR.sup.8).sub.p--(CR.sup.6R.sup.7).sub.m--(CR.sup.4R.sup.5).su-
b.n; R.sup.4, R.sup.6 and R.sup.8 are independently H, hydroxyl or
.dbd.O with the meaning of carbonyl; R.sup.5, R.sup.7 and R.sup.9
are independently H or are absent; m, n and p are independently an
integer comprised between 0 and 2; m+n+p.gtoreq.4; R.sup.3 is
NH.sub.2 or NHR.sup.10; R.sup.10 is linear or branched
C.sub.1-C.sub.6 alkyl; linear or branched C.sub.1-C.sub.6
hydroxyalkyl; linear or branched
(C.sub.1-C.sub.3)alkoxy(C.sub.1-C.sub.6)alkyl;
amino(C.sub.1-C.sub.6)alkyl, where the amino group is optionally
substituted with one or two linear or branched C.sub.1-C.sub.3
alkyl groups; C.sub.6-C.sub.14 aryl; or C.sub.6-C.sub.14
aryl(C.sub.1-C.sub.6)alkyl, wherein said C.sub.6-C.sub.14 aryl
group is optionally substituted by one or more substituents, which
are the same or different, selected from the group consisting of
halogen; hydroxyl; linear or branched, saturated or unsaturated
C.sub.1-C.sub.6 alkoxy; and amino, where the amino group is
optionally substituted with one or two linear or branched
C.sub.1-C.sub.6 alkyl groups; or an optically active form, or
pharmaceutically acceptable salt thereof; with the proviso that
R.sup.4, R.sup.6 and R.sup.8 are not all H at the same time.
17. The compound according to claim 16 wherein n=2, m=1 and
p.gtoreq.1.
18. The compound according to claim 16, wherein R.sup.6 is OH or =0
with the meaning of carbonyl.
19. The compound according to claim 16 wherein n=1 and R.sup.4 is
OH or .dbd.O with the meaning of carbonyl.
20. The compound according to claim 16 which is
4-(6-amino-9-methyl-8 [1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol,
1-(6-amino-9-methyl-8 [1,2,3
]triazol-2-yl-9H-purin-2-yl)butan-1-ol,
4-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-one,
4-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl) butan-2-ol,
or
1-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-1-one
or a pharmaceutically acceptable salt thereof.
21. The compound of claim 16 which is
4-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl) butan-2-one
or a pharmaceutically acceptable salt thereof.
22. A pharmaceutical composition comprising at least one compound
according to claim 16 or an optically active form, or a
pharmaceutically acceptable salt thereof and at least one
pharmaceutically acceptable vehicle and/or excipient.
23. The pharmaceutical composition according to claim 22 wherein
the compound is
4-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol,
1-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol,
4-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-one,
4-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl)butan-2-ol,
or
1-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-1-one
or a pharmaceutically acceptable salt thereof.
24. The pharmaceutical composition according to claim 22 which
further comprises L-DOPA.
25. A process for preparing a pharmaceutical composition comprising
mixing at least one compound according to claim 16 or an optically
active form, or a pharmaceutically acceptable salt thereof with at
least one pharmaceutically acceptable vehicle and/or excipient.
26. A method for treating a pathological state for which the
modulation of A.sub.2A activity would result at improving the
health of a patient which comprises administering an effective
amount of compound according to claim 16 or an optically active
form, or a pharmaceutically acceptable salt thereof to a patient in
need thereof.
27. The method according to claims 26 wherein the pathological
state is a motor disorder.
28. The method according to claim 27, wherein said motor disorder
is Parkinson's disease, Alzheimer's disease, Huntington's disease,
Wilson's disease or Hallervorden-Spatz disease.
29. The method according to claim 26 wherein said pathological
state is cerebral ischaemia optionally associated with
neurodegenerative processes.
30. A method for treating Parkinson's disease which comprises
administering an effective amount of the pharmaceutical composition
according to claim 24 to a patient in need thereof.
31. A process for synthesizing a compound of claim 16, which
comprises reacting a compound of the formula II ##STR00009##
wherein R.sup.1 is C.sub.1-C.sub.6 linear or branched alkyl;
.sub.R11 is N(.sub.R.sup.13).sub.2; R.sup.13 is benzyl,
p-(Me0)-benzyl, p-(C1)-benzyl or p-(Br)-benzyl; R.sup.12 is Cl;
with a compound of formula IX ##STR00010## wherein R.sup.14 and
R.sup.15 are at each occurrence independently H or OH; V is 2 or 3;
in the presence of Hermann's catalyst and sodium acetate in a polar
solvent.
Description
RELATED APPLICATIONS AND INCORPORATION BY REFERENCE
[0001] This application is a Divisional of U.S. application Ser.
No. 13/257,750 filed Nov. 14, 2011, which is a National Stage Entry
of PCT/EP2010/053554 filed Mar. 18, 2010, which published as PCT
Publication No. WO 2010/106145 on Sep. 23, 2010, which claims
benefit of European Patent Application EP 09155690.2 filed Mar. 20,
2009.
[0002] The foregoing applications, and all documents cited therein
or during their prosecution ("appin cited documents") and all
documents cited or referenced in the appin cited documents, and all
documents cited or referenced herein ("herein cited documents"),
and all documents cited or referenced in herein cited documents,
together with any manufacturer's instructions, descriptions,
product specifications, and product sheets for any products
mentioned herein or in any document incorporated by reference
herein, are hereby incorporated herein by reference, and may be
employed in the practice of the invention. More specifically, all
referenced documents are incorporated by reference to the same
extent as if each individual document was specifically and
individually indicated to be incorporated by reference.
FIELD OF THE INVENTION
[0003] The present invention relates to new triazolyl purine
derivatives, processes for their preparation, and to pharmaceutical
compositions containing them for the treatment of neurological
disorders for which inhibition of adenosine A.sub.2A receptor will
result at improving the health state of a patient.
BACKGROUND OF THE INVENTION
[0004] Adenosine A.sub.2 is an endogenous modulator, which among
other effects mediates a general depression of the central nervous
system, vasodilatation and inhibition of platelet aggregation.
[0005] Adenosine receptors represent a subclass (P1) of the group
of purine nucleotide and nucleoside receptors known as
purinoreceptors. Up to now, four subtypes of adenosine receptors
are known (i.e., A.sub.1, A.sub.2A, A.sub.2B (of high and low
affinity) and A.sub.3 receptors). Adenosine receptors are all
coupled to G-proteins; A.sub.1 and A.sub.3 subtypes are associated
with inhibitory G-proteins and the A.sub.2A and A.sub.2B subtypes
are associated with stimulatory G-proteins. Activation of the
A.sub.1 and A.sub.3 receptors causes inhibition of adenylate
cyclase and phospholipase C, which inhibits neurotransmission. The
A.sub.1 receptors are highly expressed in the brain, especially in
the hippocampus, thalamus, cerebellum and cortex compared to the
A.sub.3 receptors which are moderately expressed in the brain.
Activation of the A.sub.2A and A.sub.2B receptors causes activation
of adenylate cyclase and phospholipase C, resulting in the
stimulation of neurotransmission. A.sub.2A receptors are
co-expressed in the brain with dopamine D2 receptors, especially in
the striatum, olfactory tubercle and nucleus accumbens and are
involved in neurodegenerative pathologies.
[0006] A.sub.2a receptors are densely distributed in the central
nervous system (striatum, nucleus accumbens and olfactory
tubercles) where they play an important role in the regulation of
mood and motor activity (Poulsen, S. A., et al., Bioorg. Med.
Chem., 1998, 6, 619; Ongini, E., et al., Trends Pharmacol. Sci.,
1996, 17, 364). Parkinson's disease has been treated for more than
thirty years by dopamine replacement strategies (Cotzias, G. C., et
al., N. Engl. J. Med., 1969, 280, 337). However, because long-term
use of dopamine-replacing agents is associated with severely
disabling side effects, most notably dyskinesia (Chase T. N.,
Neurology, 1998, 50, S17-S25), non-dopaminergic treatments as
monotherapies were judged as a promising strategy to treat such a
disease (Brotchie, J. M., Curr. Opin. Neurol., 1997, 10, 340).
Moreover, some scientific evidences also suggest that increased
synthesis of adenosine A.sub.2a receptors in striatopallidal
pathway neurons is associated with the development of dyskinesias
following long-term levodopa therapy in Parkinson's disease (Calon,
F., et al., Brain, 2004, 127, 1075; Xiao, D., et al., J. Neurosci.,
2006, 26, 52, 13548). A.sub.2A antagonists, in association with a
low dose of L-DOPA, displayed antiparkinsonian activity similar to
that produced by a full dose of L-DOPA without exacerbating
abnormal motor side effects (Tronci E., et al. Eur J. Pharmacol.,
2007, 566, 94; Jenner P., Expert Opin. Investig. Drugs, 2005, 14,
6, 729).
[0007] Adenosine has also been implicated in numerous other
pathologies such as epilepsy, cerebral ischaemic preconditioning,
sleep and immune reaction within the brain (Brundege, J. M., et
al., Adv. Pharma., 1997, 39, 353).
[0008] Imidazopyrimidine derivatives of formula A as antidiabetic
compounds are disclosed in U.S. Pat. No. RE39112 E (Eisai Co.,
Ltd.).
##STR00001##
[0009] 94% of the latter compounds (223 out of 237 exemplified
compounds) present a fluoro-containing phenyl moiety as R.sup.3
group and/or a tertiary alcohol within the R.sup.1 radical,
suggesting that those moieties constitute an important feature to
confer the activity.
[0010] A patent (EP1412354) filed by the Applicant disclosed
triazolylimidazopyridine and triazolylpurine derivatives endowed of
anti-psychotic properties. However, none of the compounds of the
present invention were neither disclosed nor suggested.
DESCRIPTION OF THE INVENTION
[0011] The invention provides novel compounds of formula I, or a
hydrate or solvate thereof and compositions that include such
compounds endowed with adenosine A.sub.2a inhibiting
properties:
##STR00002## [0012] R.sup.1.dbd. is C.sub.1-C.sub.6 linear or
branched alkyl; [0013] R.sup.2 is a group of formula
R.sup.9--(CHR.sup.8).sub.p--(CR.sup.6R.sup.7).sub.m--(CR.sup.4R.sup.5).su-
b.n--; [0014] R.sup.4, R.sup.6 and R.sup.8 are at any occurrence
independently H, hydroxyl or .dbd.O with the meaning of carbonyl;
[0015] R.sup.5, R.sup.7 and R.sup.9 are at any occurrence
independently H or are absent; [0016] m, n and p are independently
an integer comprised between 0 and 2; [0017] m+n+p.gtoreq.4; [0018]
R.sup.3 is NH.sub.2, NHR.sup.10; [0019] r.sup.10 is C.sub.1-C.sub.6
alkyl or C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.3 alkoxyalkyl,
amino(C.sub.1-C.sub.6)alkyl, where the amino group is optionally
substituted with one or two C.sub.1-C.sub.3 alkyl groups, being
said alkyl groups linear or branched; C.sub.6-C.sub.14 aryl or
C.sub.6-C.sub.14 aryl(C.sub.1-C.sub.6)alkyl, with the aryl group
optionally substituted by one or more substituents, either the same
or different, selected from the group constituted by halogen,
hydroxy, C.sub.1-C.sub.6 alkoxy linear or branched saturated or
unsaturated, amino, mono- or di-substituted with C.sub.1-C.sub.6
alkyl linear or branched; [0020] their optically active forms such
as enantiomers, diastereomers and their racemate forms, and
pharmaceutically acceptable salts thereof; with the proviso that
R.sup.4, R.sup.6 and R.sup.8 are not all H at the same time.
[0021] We have found that the derivatives (I), prepared according
to the invention, are useful agents for the treatment of disease
states, disorders and pathological conditions wherein modulation of
the A.sub.2A receptor activity would result at improving the health
of the patient.
[0022] An embodiment of this invention is that of compounds of
formula I, for use as medicaments.
[0023] In another embodiment, said medicament is used for treating
a subject affected by motor disorders deriving from functional
alterations in the basal ganglia.
[0024] In a still further embodiment, said motor disorders consist
of the ones involved in diseases comprising Parkinson's disease,
Alzheimer's disease, Huntington's disease and Wilson's disease.
[0025] In another embodiment, the compounds of formula I are also
useful for the preparation of medicaments for the treatment of
cerebral ischaemia and/or associated with neurodegenerative
processes.
[0026] The term "alkyl" refers to linear or branched alkyl groups
having from 1 to 6 carbon atoms. Preferred alkyl groups are
exemplified by groups such as methyl, ethyl, n-propyl, isopropyl,
n-butyl, isobutyl, neo-butyl, tert-butyl, pentyl, iso-pentyl,
n-hexyl and the like.
[0027] The term "alkenyl" refers to linear or branched alkenyl
groups preferably having from 2 to 12 carbon atoms, or preferably,
2 to 6 carbon atoms also named "lower" alkenyl group and having at
least 1 or 2 sites of alkenyl unsaturation. Preferable alkenyl
groups include ethenyl (--CH.dbd.CH2), propenyl (allyl,
--CH.sub.2CH.dbd.CH.sub.2) and the like. The term alkenyl embraces
radicals having "cis" and "trans" orientation, or alternatively "Z"
and "E".
[0028] The term "cycloalkyl" refers to a saturated or partially
unsaturated (i.e., not aromatic) carbocyclic group of from 3 to 10
carbon atoms having a single ring or multiple condensed rings.
[0029] Examples of C.sub.3-C.sub.10 cycloalkyl include cyclopropyl,
cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, adamantyl and the
like.
[0030] The term "heterocycloalkyl" refers to a saturated or
partially unsaturated (i.e., not aromatic) five-, six- or
seven-membered ring containing one or more heteroatoms selected
from the group consisting of nitrogen, oxygen or sulfur atoms, and
which rings may be substituted with lower alkyl, lower alkenyl, or
aryl. Preferred heterocycloalkyl include pyrrolidine, piperidine,
piperazine, ketopiperazine, thiomorpholine, 2,5-diketopiprazine,
1-methylpiperazine, morpholine, dihydropyranyl, tetrahydropyranyl,
tetrahydrofuran, dihydropyrrole, imidazolidine, dihydropyrazole,
pyrazolidine and the like.
[0031] The term "aryl" refers to an aromatic carbocyclic group of 6
to 14 carbon atoms having a single ring (e. g., phenyl) or multiple
rings that may be attached in a pendent manner or may be fused.
Preferred aryl include phenyl.
[0032] The term "alkoxy" refers to the group --O--R where R
includes "C.sub.1-C.sub.6 alkyl", "C.sub.2-C.sub.6 alkenyl",
"C.sub.3-C.sub.10 cycloalkyl" and "heterocycloalkyl".
[0033] The term "alkoxyalkyl" refers to alkyl groups as above
defined having an alkoxy substituent as above defined, including
2-ethoxyethyl, methoxymethyl and the like.
[0034] The term "amino" refers to the group --NRR' where each R, R'
is independently H, "alkyl", "alkenyf", "cycloalkyl",
"heterocycloalkyl", "aryl", "heteroaryl" and where R and R',
together with the nitrogen atom to which they are attached, can
optionally form a 3 to 8-membered heterocycloalkyl ring as above
defined. The term "aminoalkyl" or "amino(C.sub.1-C.sub.6)alkyl"
refers to alkyl groups as above defined having an amino substituent
as above defined.
[0035] "Pharmaceutically acceptable salts or complexes" refers to
salts or complexes of the below identified compounds of formula
(I), that retain the desired biological activity. Examples of such
salts include, but are not restricted to acid addition salts formed
with inorganic acids (e.g. hydrochloric acid, hydrobromic acid,
sulfuric acid, phosphoric acid, nitric acid, and the like), and
salts formed with organic acids such as acetic acid, oxalic acid,
tartaric acid, succinic acid, malic acid, fumaric acid, maleic
acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid,
alginic acid, polyglutamic acid, naphthalene sulfonic acid, toluene
sulfonic acid, naphthalene disulfonic acid, methanesulfonic acid
and poly-galacturonic acid. When the salt is of a mono acid (for
example, the hydrochloride, the hydrobromide, the
p-toluenesulphonate, or the acetate), the hydrogen form of a
di-acid (for example, the hydrogen sulphate, or the succinate), or
the dihydrogen form of a tri-acid (for example, the dihydrogen
phosphate, or the citrate), at least one molar equivalent and
usually a molar excess of the acid is employed. However, when such
salts as the sulphate, the hemisuccinate, the hydrogen phosphate,
or the phosphate are desired, the appropriate and exact chemical
equivalents of acid are generally used.
[0036] "Pharmaceutically active derivative" refers to any compound
that upon administration to the patient is capable of providing
directly or indirectly, the activity disclosed herein.
[0037] The compounds according to formula I could be employed alone
or in combination with further pharmaceutical agents such as
L-DOPA.
[0038] The compounds of the present invention may be prepared from
readily available starting materials using the following general
methods and procedures. It will be appreciated that where typical
or preferred experimental conditions (i.e., reaction temperatures,
time, moles of reagents, solvents, etc.) are given, other
experimental conditions can also be used unless otherwise stated.
Optimum reaction conditions may vary with the particular reactants
or solvents used, but such conditions can be determined by one
skilled in the art by routine optimisation procedures.
[0039] When employed as pharmaceuticals, the compounds of the
present invention are typically administered in the form of a
pharmaceutical composition. Hence, pharmaceutical compositions
comprising a compound of formula (I) and a pharmaceutically
acceptable carrier, diluent or excipient therefore is also within
the scope of the present invention. Such compositions can be
prepared in a manner well known in the pharmaceutical art and
comprise at least one active compound. A person skilled in the art
is aware of a whole variety of such carrier, diluent or excipient
compounds suitable to formulate a pharmaceutical composition.
[0040] The compounds of the present invention, together with a
conventionally employed adjuvant, carrier, diluent or excipient may
be placed into the form of pharmaceutical compositions and unit
dosages thereof, and such forms may be employed as solids, such as
tablets or filled capsules, or liquids such as solutions,
suspensions, emulsions, elixirs, or capsules filled with the same,
all for oral use, or in the form of sterile injectable solutions
for parenteral (including subcutaneous use). Such pharmaceutical
compositions and unit dosage forms thereof may comprise ingredients
in conventional proportions, with or without additional active
compounds or principles, and such unit dosage forms may contain any
suitable effective amount of the active ingredient commensurate
with the intended daily dosage range to be employed.
[0041] Generally, the compounds of this invention are administered
in a "pharmaceutically effective amount". The amount of the
compound actually administered will typically be determined by a
physician, in the light of the relevant circumstances, including
the condition to be treated, the chosen route of administration,
the actual compound administered, drug combination, the age, body
weight, and response of the individual patient, the severity of the
patient's symptoms, and the like. Generally, an effective dose will
be from 0.01 mg/kg to 100 mg/kg, preferably 0.05 mg/kg to 50 mg/kg.
Compositions may be administered individually to a patient or may
be administered in combination with other agents, drugs or
hormones. For any compound, the therapeutically effective dose can
be estimated initially either in cell culture assays or in animal
models, usually mice, rats, guinea pigs, rabbits, dogs, or
pigs.
[0042] The animal model may also be used to determine the
appropriate concentration range and route of administration. Such
information can then be used to determine useful doses and routes
for administration in humans. In calculating the Human Equivalent
Dose (HED) it is recommended to use the conversion table provided
by the FDA in Guidance for Industry and Reviewers document
available from FDA. The pharmaceutical compositions of this
invention can be administered by a variety of routes including
oral, rectal, sublingual, transdermal, subcutaneous, intravenous,
intramuscular, intrathecal, intraperitoneal, intranasal and locally
on the diseased tissue after surgical operation.
[0043] Depending on the intended route of delivery, the compounds
are preferably formulated as parenteral, topical or oral
compositions. The compositions for oral administration may take the
form of bulk liquid solutions or suspensions, or bulk powders. More
commonly, however, the compositions are presented in unit dosage
forms to facilitate accurate dosing. The term "unit dosage forms"
refers to physically discrete units suitable as unitary dosages for
human subjects and other mammals, each unit containing a
predetermined quantity of active material calculated to produce the
desired therapeutic effect, in association with a suitable
pharmaceutical excipient. Typical unit dosage forms include
refilled, pre-measured ampoules or syringes of the liquid
compositions or pills, tablets, capsules or the like in the case of
solid compositions. In such compositions, the compound of the
invention is usually a minor component (from about 0.1 to about 50%
by weight or preferably from about 1 to about 40% by weight) with
the remainder being various vehicles or carriers and processing
aids helpful for forming the desired dosing form.
[0044] Dosage treatment may be a single dose schedule or a multiple
dose schedule. Liquid forms suitable for oral administration may
include a suitable aqueous or non-aqueous vehicle with buffers,
suspending and dispensing agents, colorants, flavours and the
like.
[0045] Solid forms may include, for example, any of the following
ingredients, or compounds of a similar nature: a binder such as
microcrystalline cellulose, acacia, gum tragacanth, gelatine or
polyvinyl-pyrrolidone; an excipient such as starch or lactose, a
disintegrating agent such as alginic acid, primogel, or potato or
corn starch; a lubricant such as magnesium stearate, talc,
polyethylene glycol or silica; a glidant such as colloidal silicon
dioxide; a sweetening agent such as sucrose or saccharin; or a
flavoring agent such as peppermint, methyl salicylate, or orange
flavoring. The tablets may be coated according to methods well
known to people skilled in the art of pharmaceutical practice.
[0046] Parenteral compositions are typically based upon injectable
sterile saline or phosphate-buffered saline or other injectable
earners known in the art. As mentioned above, the compound of
formula I in such compositions is typically a minor component,
frequently ranging between 0.05 to 10% by weight with the remainder
being the injectable carrier and the like.
[0047] The compounds of this invention can also be administered in
sustained release forms or from sustained release drug delivery
systems. A description of representative sustained release
materials can also be found in the incorporated materials in
Remington's Pharmaceutical Sciences.
[0048] The above-described components for orally administered or
parenteral compositions are merely representative. Further
materials as well as processing techniques and the like are set out
in Part 5 of Remington's Pharmaceutical Sciences, 20th Edition,
2000, Mack Publishing Company, Easton, Pa., which is incorporated
herein be reference.
[0049] A further embodiment of the invention is a process for the
preparation of pharmaceutical compositions characterised by mixing
one or more compounds of formula (I) with suitable excipients,
stabilizers and/or pharmaceutically acceptable diluents.
[0050] As above disclosed, the compounds of the present invention
are useful as medicaments due to their Aza modulating properties
for the treatment of disorders where such modulation result in
improving the health of the patient. In particular, patients
suffering from Parkinson's disease, Alzheimer's disease,
Huntington's disease, Wilson's disease, psychiatric disorders,
Hallervorden-Spatz disease, progressive pallidal atrophy and
diabetes can be treated.
[0051] Objects of the present invention are pharmaceutical
compositions containing compounds of formula I, as described
earlier, in combination with excipients and/or pharmacologically
acceptable diluents.
[0052] A further embodiment of the invention is a process for the
preparation of compounds of formula I as defined above. The
compounds of the invention can be prepared by conventional
synthetic methods and are described underneath.
Method A
[0053] Compounds of formula (I), wherein [0054] R.sup.1.dbd. is
C.sub.1-C.sub.6 linear or branched alkyl; [0055] R.sub.2 is a group
of formula
R.sup.9--(CHR.sup.8).sub.p--(CR.sup.6R.sup.7).sub.m--(CR.sup.4R.s-
up.5).sub.n--; [0056] R.sup.4, R.sup.5, R.sup.7, and R.sup.9 are H;
[0057] R.sup.6 and R.sup.8 are at any occurrence independently H or
hydroxyl with at least one of them being hydroxyl; [0058] m and p
are independently an integer comprised between 0 and 2; [0059] n is
1 or 2; [0060] m+n+p.gtoreq.4; [0061] R.sup.3 is NH.sub.2,
NHR.sup.10; and [0062] R.sup.10 is C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.3 alkoxyalkyl,
amino(C.sub.1-C.sub.6)alkyl, where the amino group is optionally
substituted with one or two C.sub.1-C.sub.3 alkyl groups, being
said alkyl groups linear or branched; C.sub.6-C.sub.14 aryl or
C.sub.6-C.sub.14 aryl(C.sub.1-C.sub.6)alkyl, with the aryl group
optionally substituted by one or more substituents, either the same
or different, selected from the group constituted by halogen,
hydroxy, C.sub.1-C.sub.6 alkoxy linear or branched saturated or
unsaturated, amino, mono- or di-substituted with C.sub.1-C.sub.6
alkyl linear or branched; [0063] can be synthesized by a process
comprising the reaction of a compound of formula II
[0063] ##STR00003## [0064] wherein [0065] R.sup.1 is
C.sub.1-C.sub.6 linear or branched alkyl; [0066] R.sup.H is
N(R.sup.13).sub.2; [0067] R.sup.13 is benzyl, p-(MeO)-benzyl,
p-(Cl)-benzyl or p-(Br)-benzyl; [0068] R.sup.12 is Cl; [0069] with
a compound of formula III
[0069]
R.sup.9--(CHR.sup.8a).sub.p--(CR.sup.6aR.sup.7).sub.m--(CR.sup.4R-
.sup.5).sub.n--MgX Formula III, [0070] wherein, [0071] X is Cl or
Br; [0072] R.sup.4, R.sup.5, R.sup.7, and R.sup.9 are H; [0073]
R.sup.6a and R.sup.8a are at any occurrence independently OH or H
with at least one of them being OH; [0074] m and pare independently
an integer comprised between 0 and 2;
[0075] n is 1 or 2; [0076] m+n+p.gtoreq.4; [0077] in the presence
of Fe(acac).sub.3 in an aprotic solvent such as THF or NMP at a
temperature ranging from 0.degree. C. to RT.
Method B
[0078] Compounds of formula (I), wherein [0079] R.sup.1 is
C.sub.1-C.sub.6 linear or branched alkyl; [0080] R.sup.2 is a group
of formula
R.sup.9--(CHR.sup.8).sub.p--(CR.sup.6R.sup.7).sub.m--(CR.sup.4R.s-
up.5).sub.n--; [0081] R.sup.4 and R.sup.5 are H; [0082] R.sup.6 and
R.sup.8 are at any occurrence independently H or .dbd.O with the
meaning of carbonyl; with at least one of R.sup.6 and R.sup.8 being
.dbd.O with the meaning of carbonyl; [0083] R.sup.7 and R.sup.9 are
at any occurrence independently H, or are absent in case the
corresponding carbon atom bearing said R.sup.6 or R.sup.8 group is
involved in a carbonyl bond; [0084] m and p are independently an
integer comprised between 0 and 2; [0085] n is 1 or 2; [0086]
m+n+p.gtoreq.4; [0087] R.sup.3 is NH.sub.2, NHR.sup.10; [0088]
R.sup.10 is C.sub.1-C.sub.6 alkyl or C.sub.1-C.sub.6 hydroxyalkyl,
C.sub.1-C.sub.3 alkoxyalkyl, amino(C.sub.1-C.sub.6)alkyl, where the
amino group is optionally substituted with one or two
C.sub.1-C.sub.3 alkyl groups, being said alkyl groups linear or
branched; C.sub.6-C.sub.14 aryl or C.sub.6-C.sub.14
aryl(C.sub.1-C.sub.5)alkyl, with the aryl group optionally
substituted by one or more substituents, either the same or
different, selected from the group constituted by halogen, hydroxy,
C.sub.1-C.sub.6 alkoxy linear or branched saturated or unsaturated,
amino, mono- or di-substituted with C.sub.1-C.sub.6 alkyl linear or
branched; [0089] can be synthesized by a process comprising the
reaction of a compound of formula II as defined above, with a
compound of formula IV
[0089]
H--(CH.sub.2).sub.q--(CR.sup.6bR.sup.6c).sub.r--(CH.sub.2).sub.s--
-MgX Formula IV, [0090] wherein [0091] X is C.sup.1 or Br; [0092]
R.sup.6b and R.sup.6c are at any occurrence independently both H or
when taken together with the carbon atom to which they are attached
to form a 1,3-dioxane group optionally substituted by two or more
methyl groups with at least one of the occurrence being a
1,3-dioxane group substituted by two or more methyl groups; [0093]
q is an integer comprised between 0 and 3; [0094] r and s are
independently an integer comprised between 1 and 3; with
q+r+s.gtoreq.4; in the presence of a Fe(acac).sub.3 in an aprotic
solvent such as THF or NMP at a temperature ranging from 0.degree.
C. to RT.
Method C
[0095] Compounds of formula (I), wherein [0096] R.sup.1 is
C.sup.1-C.sup.6 linear or branched alkyl; [0097] R.sup.2 is a group
of formula
R.sup.9--(CHR.sup.8).sub.p--(CR.sup.6R.sup.7).sub.m--(CR.sup.4R.s-
up.5).sub.n; [0098] R.sup.4 is hydroxyl or .dbd.O with the meaning
of carbonyl; [0099] R.sup.5 is H or is absent when R.sup.4 is =)
with the meaning of carbonyl; [0100] R.sup.6 and R.sup.8 are at any
occurrence independently H, hydroxyl or .dbd.O with the meaning of
carbonyl; [0101] R.sup.7 and R.sup.9 are at any occurrence
independently H or are absent in case the corresponding carbon atom
bearing said R.sup.6 or R.sup.8 group is involved in a carbonyl
bond; [0102] n is 1; [0103] m and p are independently an integer
comprised between 1 and 2, with m+p.gtoreq.3; [0104] R.sup.10 is
C.sub.1-C.sub.6 alkyl or C.sub.1-C.sub.6 hydroxyalkyl,
C.sub.1-C.sub.3 alkoxyalkyl, amino(C.sub.1-C.sub.6)alkyl, where the
amino group is optionally substituted with one or two
C.sub.1-C.sub.3 alkyl groups, being said alkyl groups linear or
branched; C.sub.6-C.sub.14 aryl or C.sub.6-C.sub.14
aryl(C.sub.1-C.sub.6)alkyl, with the aryl group optionally
substituted by one or more substituents, either the same or
different, selected from the group constituted by halogen, hydroxy,
C.sub.1-C.sub.6 alkoxy linear or branched saturated or unsaturated,
amino, mono- or di-substituted with C.sub.1-C.sub.6 alkyl linear or
branched; [0105] can be synthesized by a process comprising the
following steps: [0106] a) reaction of a compound of formula V
[0106] ##STR00004## [0107] wherein R.sup.1 is C.sub.1-C.sub.6
linear or branched alkyl; [0108] with i-PrMgCl; [0109] b) in situ
addition of compound formula VI
[0109] H--(CHR.sup.8d).sub.t--(CR.sup.6dR.sup.7d).sub.s--CHO
Formula VI [0110] wherein: [0111] R.sup.6d and R.sup.7d are at any
occurrence independently H or OH with at least one of them being H;
or [0112] R.sup.6d and R.sup.7d when taken together with the carbon
atom to which they are attached, form a 1,3-dioxane group
optionally substituted by two or more methyl groups; [0113]
R.sup.8d is H or hydroxyl; [0114] s and t are independently an
integer comprised between 1 and 2, with s+t.gtoreq.3; [0115] in an
aprotic solvent such as THF at a temperature ranging from
-78.degree. C. to RT.
Method D
[0116] Compounds of formula (I), wherein [0117] R.sup.1.dbd. is
C.sub.1-C.sub.6 linear or branched alkyl; [0118] R.sub.2 is a group
of formula
R.sup.9--(CHR.sup.8).sub.p--(CR.sup.6R.sup.7).sub.m--(CR.sup.4R.s-
up.5).sub.n--; [0119] R.sup.4 and R.sup.5 are H; [0120] R.sup.6 and
R.sup.8 are at any occurrence independently H, hydroxyl or .dbd.O
with the meaning of carbonyl; [0121] R.sup.7 and R.sup.9 are at any
occurrence independently H or are absent in case the corresponding
carbon atom bearing said R.sup.6 or R.sup.8 group is involved in a
carbonyl bond; [0122] m and p are independently an integer
comprised between 0 and 2; [0123] n=2; [0124] m+n+p.gtoreq.4;
[0125] R.sup.3 is NH.sub.2, NHR.sup.10; [0126] R.sup.10 is
C.sub.1-C.sub.6 alkyl or C.sub.1-C.sub.6 hydroxyalkyl,
C.sub.1-C.sub.3 alkoxyalkyl, amino(C.sub.1-C.sub.6)alkyl, where the
amino group is optionally substituted with one or two
C.sub.1-C.sub.3 alkyl groups, being said alkyl groups linear or
branched; C.sub.6-C.sub.14 aryl or C.sub.6-C.sub.14
aryl(C.sub.1-C.sub.6)alkyl, with the aryl group optionally
substituted by one or more substituents, either the same or
different, selected from the group constituted by halogen, hydroxy,
C.sub.1-C.sub.6 alkoxy linear or branched saturated or unsaturated,
amino, mono- or di-substituted with C.sub.1-C.sub.6 alkyl linear or
branched; [0127] can be synthesized by a process comprising the
reaction of a compound of formula VII
[0127] ##STR00005## [0128] wherein [0129] R.sup.1.dbd. is
C.sub.1-C.sub.6 linear or branched alkyl; with a compound of
formula VIII
[0129] ##STR00006## [0130] wherein [0131] R.sup.6 is at any
occurrence independently H or hydroxyl, [0132] u is an integer
equal to or greater than 2; [0133] in the presence of
bis-triphenylphosphine palladium dichloride, CuI and optionally a
tertiary amine such as triethylamine in a polar solvent such as
dioxane at a temperature ranging from 0.degree. C. to RT.
Method E
[0134] Compounds of formula (I), wherein [0135] R.sup.1.dbd. is
C.sub.1-C.sub.6 linear or branched alkyl; [0136] R.sup.2 is a group
of formula
R.sup.9--(CHR.sup.8).sub.p--(CR.sup.6R.sup.7).sub.m--(CR.sup.4R.s-
up.5).sub.n--; [0137] R.sup.4, R.sup.6 and R.sup.8 are at any
occurrence independently H, hydroxyl or .dbd.O with the meaning of
carbonyl; [0138] R.sup.5, R.sup.7 and R.sup.9 are at any occurrence
independently H or are absent in case the corresponding carbon atom
bearing said R.sup.4, R.sup.6 or R.sup.8 group is involved in a
carbonyl bond; [0139] m, n and p are independently an integer
comprised between 0 and 2; [0140] m+n+p.gtoreq.4; [0141] R.sup.3 is
NH.sub.2, NHR10; [0142] R.sup.10 is C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.3 alkoxyalkyl,
amino(C.sub.1-C.sub.6) alkyl, where the amino group is optionally
substituted with one or two C.sub.1-C.sub.3 alkyl groups, being
said alkyl groups linear or branched; C.sub.6-C.sub.14 aryl or
C.sub.6-C.sub.14 aryl(C.sub.1-C.sub.6)alkyl, with the aryl group
optionally substituted by one or more substituents, either the same
or different, selected from the group constituted by halogen,
hydroxy, C.sub.1-C.sub.6 alkoxy linear or branched saturated or
unsaturated, amino, mono- or di-substituted with C.sub.1-C.sub.6
alkyl linear or branched; [0143] can be synthesized by a process
comprising the reaction of compounds of formula II as above
described with a compound of formula IX
[0143] ##STR00007## [0144] wherein [0145] R.sup.14 is at each
occurrence independently H or OH; [0146] R.sup.15 is H or OH;
[0147] v is .gtoreq.2; [0148] in the presence of Hermann's catalyst
and sodium acetate in a polar solvent such as NMP.
Method F
[0149] Compounds of formula (I), wherein [0150] R.sup.1.dbd. is
C.sub.1-C.sub.6 linear or branched alkyl; [0151] R2 is a group of
formula
R.sup.9--(CHR.sup.8).sub.p--(CR.sup.6R.sup.7).sub.m--(CR.sup.4R.sup.5).su-
b.n--; [0152] R.sup.4 and R.sup.5 are H; [0153] R.sup.6 and R.sup.8
are at any occurrence independently H, hydroxyl or .dbd.O with the
meaning of carbonyl; [0154] R.sup.7 and R.sup.9 are at any
occurrence independently H or are absent; [0155] m and p are
independently an integer comprised between 0 and 2; [0156]
n.gtoreq.1; [0157] m+n+p.gtoreq.4; [0158] R.sup.3 is NH.sub.2,
NHR.sup.10; [0159] R.sup.10 is C.sub.1-C.sub.6 alkyl or
C.sub.1-C.sub.6 hydroxyalkyl, C.sub.1-C.sub.3 alkoxyalkyl,
amino(C.sub.1-C.sub.6)alkyl, where the amino group is optionally
substituted with one or two C.sub.1-C.sub.3 alkyl groups, being
said alkyl groups linear or branched; C.sub.6-C.sub.14 aryl or
C.sub.6-C.sub.14 [0160] aryl(C.sub.1-C.sub.6)alkyl, with the aryl
group optionally substituted by one or more substituents, either
the same or different, selected from the group constituted by
halogen, hydroxy, C.sub.1-C.sub.6 alkoxy linear or branched
saturated or unsaturated, amino, mono- or di-substituted with
C.sub.1-C.sub.6 alkyl linear or branched; [0161] can be synthesized
by a process comprising the reaction of compounds of formula VII as
above described with a compound of formula X
[0161]
R.sup.9--(CHR.sup.8).sub.p--(CR.sup.6dR.sup.7d).sub.m--(CR.sup.4R-
.sup.5).sub.n--ZnBr Formula X;
wherein [0162] R.sup.4 and R.sup.5 are H; [0163] R.sup.6d and
R.sup.7d are at any occurrence independently H or OH with at least
one of them being H; or [0164] R.sup.6d and R.sup.7d when taken
together with the carbon atom to which they are attached, form a
1,3-dioxane group optionally substituted by two or more methyl
groups; [0165] R.sup.8 is at any occurrence independently H or
hydroxyl; [0166] R.sup.9 is H; [0167] m and p are independently an
integer comprised between 0 and 2; [0168] n.gtoreq.1; [0169]
m+n+p.gtoreq.4; [0170] in a polar solvent such as THF.
[0171] In all said transformations, any interfering reactive group
can be protected and then deprotected according to well-established
procedures described in organic chemistry (see for example: Greene
T. W. and P. G. M. Wuts "Protective Groups in Organic Synthesis",
J. Wiley & Sons, Inc., 3rd Ed., 1999) and well known to those
skilled in the art.
DESCRIPTION OF THE DRAWING
[0172] FIG. 1: it shows the efficacy of ST3932 at antagonizing the
haloperidol-induced catalepsy in mice.
[0173] FIG. 2: it shows the efficacy of ST4206 at increasing the
number of 5 contralateral rotation of 6-OHDA lesioned rats.
[0174] FIG. 3: it shows the efficacy of ST3829 at increasing the
number of contralateral rotation of 6-OHDA lesioned rats.
[0175] FIG. 4: it shows the efficacy of ST3932 at increasing the
number of contralateral rotation of 6-OHDA lesioned rats.
[0176] FIG. 5: it shows the efficacy of ST4206 at increasing the
number of contralateral rotation of 6-OHDA lesioned rats.
EXAMPLES
Abbreviations
[0177] AcOEt: ethyl acetate
[0178] atm: atmosphere
[0179] bs: broad singlet
[0180] DCM: dichloromethane
[0181] DMEM: Dulbecco's modified eagle's medium
[0182] DMSO: dimethylsyulfoxide
[0183] EDTA: ethylenediaminetetraacetic acid
[0184] Et.sub.2O: diethyl ether
[0185] FBS: foetal Bovine Serum
[0186] MeOH: methanol
[0187] MgCl.sub.2: magnesium dichloride
[0188] MS: mass spectrum
[0189] Na.sub.2SO.sub.4: sodium sulphate
[0190] NEt.sub.a: triethyl amine
[0191] NMP: N-methyl pyrrolidinone
[0192] PBS: phosphate-buffered saline
[0193] PCC: pyridinium chlorochromate
[0194] RP-HPLC: reversed phase-high-performance liquid
chromatography
[0195] Rt: retention time
[0196] RT: room temperature
[0197] TfOH: Trifluoromethanesulfonic acid
[0198] General Remarks: .sup.1H spectra were recorded in CDCl.sub.3
or DMSO-d.sub.6 solution as indicated, at 200 MHz with a Bruker
instrument. The chemical shift values are given in ppm and the
coupling constants in Hz. Flash column chromatography was carried
out using silica gel (Merck 230-400 mesh).
[0199] Chiral chromatography was performed using a HPLC Shimadzu
LC-10AS chromatograph connected with a Vis-UV SPD 10A Shimadzu
detector and a Shimadzu C-R6A chromatopak integrator. The
stationary phase consisted of a Chiralpak AD-H column, Daicel
Chemical industries (Chiral France) [Amylose
tris(3,5-dimethylphenylcarbamate) coated on 5 mm silica-gel] of
diameter 0.46 cm, length 25 cm. The mobile phase consisted of
n-hexane/2-propanol: 9/1 at a flow equal to 1 ml/min, .lamda.289
nm.
Example 1
4-(6-Amino-9-methyl-8 [1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol
(ST4023)
STEP A: 4-(6-Chloro-9-methyl-9H-purin-2-yl)but-3-yn-1-ol
[0200] NEt.sub.3 (4.9 ml, 34.5 mmol) and but-3-yn-1-ol (1.1 ml,
25.63 mmol) were added to a solution of
6-chloro-2-iodo-9-methyl-9H-purine (6.8 g, 23.3 mmol), CuI (454 mg,
2.23 mmol) and bis-triphenylphosphine palladium dichloride (811 mg,
1.15 mmol) in dioxane (93 ml). The reaction mixture was stirred at
RT for 1 h. The solvents were removed under reduced pressure. Water
(50 ml) was added to the dark residue obtained. The aqueous phase
was extracted with DCM (3.times.100 ml). The combined organic
phases were dried over anhydrous sodium sulphate and evaporated
under reduced pressure. The residue was purified by flash
chromatography (DCM/MeOH: 94/6) to give an off-white
precipitate.
[0201] Yield 77%.
[0202] .sup.1H NMR (DMSO-d.sub.6) .delta.: 2.67 (t, 2H, J=6.82 Hz),
3.68 (t, 2H, J=6.82 Hz), 3.86 (s, 3H), 5.01 (bs, 1H), 8.68 (s,
1H).
[0203] .sup.13C NMR (DMSO-d.sub.6) .delta.: 23.33, 30.63, 59.62,
80.55, 88.11, 130.42, 144.73, 148.86, 149.28, 152.79
[0204] MS(ESI) m/e: 237-239 (M+H)+
STEP B: 4-(6-Amino-9-methyl-9H-purin-2-yl)but-3-yn-1-ol
[0205] To a solution of
4-(6-chloro-9-methyl-9H-purin-2-yl)but-3-yn-1-ol (650 mg, 2.74
mmol) in dioxane (4 ml) was added 30% w/w water solution of ammonia
(8 ml). The reaction mixture was stirred overnight in an autoclave
at 70.degree. C.
[0206] The solution was evaporated at atmospheric pressure at
50.degree. C. to remove the ammonia. The reaction mixture was
maintained at RT for 2 h, to give a white precipitate. The solid
was filtered and dried under vacuum.
[0207] Yield 78%.
[0208] .sup.1H NMR (DMSO-d.sub.6) .delta.: 2.52 (t, 2H, J=6.82 Hz),
3.58 (dt, 2H, J=6.82 Hz, J=5.5 Hz), 3.68 (s, 3H), 4.90 (t, 1H,
J=5.5 Hz), 7.25 (bs, 2H), 8.09 (s, 1H).
[0209] .sup.13C NMR (DMSO-d.sub.6) .delta.: 23.24, 29.84, 59.95,
82.23, 83.46, 118.51, 142.58, 146.01, 150.38, 156.05
[0210] MS(ESI) m/e: 218 (M+H).sup.+
STEP C: 4-(6-Amino-9-methyl-9H-purin-2-yl)butan-1-ol
[0211] To a solution of
4-(6-amino-9-methyl-9H-purin-2-yl)-but-3-yn-1-ol (1.5 g, 6.88 mmol)
in ethanol (30 ml) was added palladium 10% on graphite (1.35 g, 20%
in weight). The mixture was stirred for 16 h in autoclave at
50.degree. C. under 4 atm of hydrogen. The catalyst was filtered
through a small pad of Celite and the solution obtained was
evaporated under reduced pressure, to give a residue that was used
for the following reaction without further purification.
[0212] Yield 70%.
[0213] .sup.1H NMR (DMSO-d.sub.6) .delta.: 1.49 (m, 2H), 1.70 (m,
2H), 2.55 (t, 2H), 3.39 (m, 2H), 3.67 (s, 3H), 4.34 (bs, 1H), 7.01
(s, 2H), 7.97 (s, 1H).
[0214] .sup.13C NMR (DMSO-d.sub.6) .delta.: 25.54, 29.68, 32.85,
39.04, 61.09, 117.39, 141.33, 151.04, 156.05, 164.93
[0215] MS(ESI) m/e: 222.0 (M+H).sup.+
STEP D: 4-(6-Amino-8-bromo-9-methyl-9H-purin-2-yl)butan-1-ol
[0216] Bromine (0.4 ml, 6.8 mmol) was added dropwise, at
-14.degree. C., to 4-(6-amino-9-methyl-9H-purin-2-yl)butan-1-ol
(250 mg, 1.13 mmol) dissolved in a mixture of dioxane (5 ml) and
acetate buffer pH 4 (2.5 ml) (obtained by dissolving 4 g of sodium
acetate in 100 ml of water and by adjusting to pH 4 with glacial
acetic acid). The reaction was stirred at this temperature for 10
minutes and then at RT for 15 minutes. Excess of bromine was
eliminated with sodium metabisulphite and the reaction brought to
pH 8 by addition of saturated solution of Na.sub.2CO.sub.3. The
aqueous phase was extracted with DCM (6.times.10). The organic
phases were dried over anhydrous sodium sulphate and evaporated
under reduced pressure, to give a residue that was used for the
following reaction without further purification.
STEP E: 4-(6-Amino-9-methyl-8
[1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol (ST4023)
[0217] To a solution of
4-(6-amino-8-bromo-9-methyl-9H-purin-2-yl)butan-1-ol (1.4 g, 4.56
mmol) in anhydrous DMF (20 ml) were added Cs2CO3 (5.9 g, 18.24
mmol) and then 1H-1,2,3-triazole (1.2 g, 1.0 ml, 17.2 mmol). The
mixture was stirred overnight at 90.degree. C. The solvent was
evaporated under reduced pressure to give a residue that was
purified by flash chromatography (DCM/MeOH: 93/7).
[0218] Yield 30%.
[0219] .sup.1H NMR (DMSO-d.sub.6) .delta.: 1.46 (m, 2H), 1.73 (m,
2H), 2.67 (t, 2H, J=7.5 Hz), 3.38 (m, 2H), 3.76 (s, 3H), 4.38 (bs,
1H), 7.38 (s, 2H), 8,31 (s, 2H).
[0220] .sup.13C NMR (DMSO-d.sub.6) .delta.: 25.43, 30.65, 32.80,
39.15, 61.04, 114.92, 138.06, 141.42, 151.14, 156.17, 166.17
[0221] MS(ESI) m/e: 289 (M+H).sup.+
Example 2
4-(6-Amino-9-methyl-8 [1,2,3]triazol-2-yl-9H-purin-2-yl)butan-2-ol
(ST3932)
STEP A: 4-(6-Chloro-9-methyl-9H-purin-2-yl)but-3-yn-2-ol
[0222] To a solution of 6-chloro-2-iodo-9-methyl-9H -purine (6.8 g,
23.3 mmol), CuI (454 mg, 2.23 mmol) and bis-triphenylphosphine
palladium dichloride (811 mg, 1.15 mmol) in dioxane (93 ml) were
added triethylamine (4.9 ml, 34.5 mmol) and but-3-yn-2-ol (1.1 ml,
25.63 mmol). The reaction mixture was stirred at RT for 1 h. The
volatiles were removed under reduced pressure. Water (50 ml) was
added to the dark residue obtained. The aqueous phase was extracted
with DCM (3.times.100 ml). The combined organic phases were dried
over anhydrous sodium sulphate and evaporated under reduced
pressure. The combined organic phases were dried over anhydrous
sodium sulphate and evaporated under reduced pressure. The residue
was purified by flash chromatography (DCM/MeOH: 94/6).
[0223] Yield 77%.
[0224] .sup.1H NMR (CDCl.sub.3) .delta.: 1.62 (d, 3H, J=6.67 Hz),
3.95 (s, 3H), 4.81 (q, 1H, J=6.64), 8.17 (bs, 1H).
[0225] .sup.13C NMR (CDC.sub.13) .delta.: 23.52, 29.72, 57.31,
81.41, 89.94, 130.59, 144.75, 148.20, 149.21, 152.65.
[0226] MS(ESI) m/e: 237-239 (M+H).sup.+
STEP B: 4-(6-Amino-9-methyl-9H-purin-2-yl)but-3-yn-2-ol
[0227] To a solution of 4-(6-chloro-9-methyl-9H-purin-2-yl)
but-3-yn-2-ol (4.8 g, 20.34 mmol) in dioxane (30 ml) was added 30%
w/w water solution of ammonia (60 ml). The reaction mixture was
stirred overnight in an autoclave at 70.degree. C. The solution was
evaporated at atmospheric pressure at 50.degree. C. and then under
reduced pressure. The residue was purified by flash chromatography
(DCM/MeOH: 97/3).
[0228] Yield 78%.
[0229] 1H NMR (DMSO-d.sub.6) .delta.: 1.42 (d, 3H, J=6.67 Hz), 3.75
(s, 3H), 4.61 (q, 1H), 5.71 (bs, 1H), 7.42 (bs, 2H) 8.17 (s,
1H).
[0230] 13C NMR (DMSO-d6) .delta.: 24.75, 29.89, 56.83, 83.14,
87.63, 130.01, 142.74, 145.65, 150.28, 156.07
[0231] MS(ESI) m/e: 218 (M+H).sup.+
STEP C: 4-(6-Amino-9-methyl-9H-purin-2-yl)butan-2-ol
[0232] 4-(6-Amino-9-methyl-9H -purin-2-yl)but-3-yn-2-ol (1.5 g,
6.88 mmol) was placed in an autoclave with ethanol (30 ml) and
palladium 10% on graphite (0.350 g, 20% in weight) was added. The
mixture was stirred overnight under 4 atm of hydrogen at 50.degree.
C. The catalyst was filtered off through Celite and the resulting
solution was evaporated under reduced pressure, to give a residue
that was used without any further purification.
[0233] Yield 70%.
[0234] .sup.1H NMR (CD.sub.3OD) .delta.: 1.21 (d, 3H, J=6.32 Hz),
1.9 (m, 2H), 2.85 (m, 2H), 3.35 (bs, 2H), 3.84 (s, 3H), 3.89 (m,
1H), 8.00 (s, 1H).
[0235] .sup.13C NMR (CD.sub.3OD) .delta.: 22.01, 28.72, 34.97,
37.72, 66.89, 116.59, 141.54, 150.37, 155.56, 165.42
[0236] MS(ESI) m/e: 222 (M+H)+
STEP D: 4-(6-Amino-8-bromo-9-methyl-9H-purin-2-yl)butan-2-ol
[0237] Bromine (2.1 ml, 41 mmol) was added dropwise at -14.degree.
C. to a solution of 4-(6-amino-9-methyl-9H-purin-2-yl)butan-2-ol
(800 mg, 3.60 mmol) in a mixture of Me0H/THF (20 ml, 1/1) and
acetate buffer pH=4 (10 ml). The latter was obtained dissolving 4 g
of sodium acetate in 100 ml of water and by adjusting to pH 4
through addition of glacial acetic acid. The reaction was stirred
at this temperature for 10 minutes and then at RT for 10 minutes.
Excess of bromine was quenched by addition of sodium metabisulphite
and the reaction was brought to pH 8 by addition of a saturated
solution of Na.sub.2CO.sub.3. The organic solvents were evaporated
under reduced pressure, to give a solid that was filtered and used
without any further purification.
[0238] Yield 76%.
STEP E: 4-(6-Amino-9-methyl-8-1,2,3]triazol-2-yl-9H-purin-2-yl)
butan-2-ol (ST3932)
[0239] To a solution of
4-(6-amino-8-bromo-9-methyl-9H-purin-2-yl)butan-2-ol (1.4 g, 4.56
mmol) in anhydrous DMF (20 ml) were added C.sub.sCO.sub.3 (5.9 g,
18.24 mmol) and 1H-1,2,3-triazole (1.2 g, 1.0 ml, 18.24 mmol). The
mixture was stirred overnight at 90.degree. C. The solvent was
evaporated under reduced pressure to give a residue that was
purified by flash chromatography (DCM/MeOH: 93/7).
[0240] Yield 27%.
[0241] .sup.1H NMR (DMSO-d.sub.6) .delta.: 1.09 (d, 3H, J=6.2 Hz),
1.78 (m, 2H), 2.72 (m, 2H), 3.66 (m, 1H), 3.77 (s, 3H), 4.45 (bs,
1H), 7.32 (bs, 2H), 8.29 (s, 2H).
[0242] .sup.13C NMR (DMSO-d.sub.6) .delta.: 24.0, 30.6, 35.9, 38.5,
66.2, 114.9, 138.0, 141.4, 151.2, 156.2, 166.4
[0243] MS(ESI) m/e: 289 (M+H).sup.+
Example 3
(S)-4-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H -purin-2-yl)
butan-2-ol (ST5748)
[0244] This compound was prepared according to the procedure
described in Example 2, using (S)-(-)-but-3-yn-2-ol in STEP 1
instead of its racemate. In STEP E, the crude reaction mixture was
purified by flash chromatography (DCM/MeOH: 95/5).
[0245] HPLC: Rt: 29 mn
Example 4
(R)-4-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H -purin-2-yl)
butan-2-ol (ST5749)
[0246] This compound was prepared according to the procedure
described in Example 2, using (R)-(-)-but-3-yn-2-ol in STEP 1
instead of its racemate. In STEP E, the crude reaction mixture was
first purified by flash chromatography (DCM/MeOH: 95/5).
[0247] HPLC: Rt: 26 mn
Example 5
1-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H -purin-2-yl)butan-l-ol
(ST3829)
STEP A: 1-(6-Chloro-9-methyl-9H-purin-2-yl)butan-1-01
[0248] To a solution of 6-chloro-2-iodo-9-methyl-9H-purine (3.7 g,
12.6 mmol) in anhydrous THE (48 ml) at -78.degree. C. under an
atmosphere of nitrogen was added isopropylmagnesium chloride (8 ml,
15.12 mmol). After 30 minutes butyraldehyde (1.7 ml, 16.38 mmol)was
added at -78.degree. C. dropwise. The reaction mixture was stirred
at -78.degree. C. for 8 h and then allowed to warm to RT overnight.
The reaction was quencend with a saturated solution of NH.sub.4Cl.
The aqueous phase was extracted with DCM (three times). The organic
phases were dried over anhydrous sodium sulphate and evaporated
under reduced pressure. The residue was purified by flash
chromatography (gradient DCM/MeOH: 98/2 to DCM/MeOH: 96/4).
[0249] Yield 59%.
[0250] .sup.1H NMR (CD.sub.3OD) .delta.: 0.96 (t, 3H, J=7.34), 1.45
(m, 2H), 1.86 (m, 2H), 3.95 (s, 3H), 4.83 (t, 1H, J=6.5), 8.47 (s,
1H).
[0251] .sup.13C NMR (CD.sub.3OD) .delta.: 12.85, 18.41, 29.22,
38.90, 73.80, 129.13, 147.46, 149.6, 152.53, 166.27.
[0252] MS (ESI+): 241-243 (M+H).sup.+
STEP B: 1-(6-Amino-9-methyl-9H-purin-2-yl)butan-1-ol
[0253] To the solution of
1-(6-chloro-9-methyl-9H-purin-2-yl)butan-1-ol (1.8 g, 7.47 mmol) in
dioxane (10 ml) was added 30% w/w water solution of ammonia (20
ml). The reaction mixture was stirred overnight in an autoclave at
70.degree. C. The solution was evaporated at atmospheric pressure
at 50.degree. C. and then under reduced pressure. The residue was
purified by flash chromatography (DCM/MeOH: 95/5).
[0254] Yield 80%.
[0255] .sup.1H NMR (DMSO-d.sub.6) .delta.: 0.93 (t, 3H, J=7.06),
1.40 (m, 2H), 1.78 (m, 2H), 3.77 (s, 3H), 4.48 (m, 1H), 4.84 (d,
1H), 7.31 (s, 2H), 8.12 (s, 1H).
[0256] .sup.13C NMR (DMSO-d.sub.6) .delta.: 14.95, 19.37, 30.29,
39.99, 73.86, 118.35, 142.33, 151.18, 156.52, 166.43.
[0257] MS (ESI+): 222 (M+H)+
STEP C: 1-(6-Amino-8-bromo-9-methyl-9H-purin-2-yl)butan-1-ol
[0258] Bromine (3.6 ml, 70.4 mmol) was added dropwise, at
--14.degree. C., to 1-(6-amino-9-methyl-9H-purin-2-yl)butan-1-ol
(1700 mg, 7.69 mmol) dissolved in a mixture of MeOH (20 ml), THF
(20 ml) and acetate buffer pH 4 (20 ml) (obtained by dissolving 4 g
of sodium acetate in 100 ml of water and by adjusting pH 4 with
glacial acetic acid). The reaction was stirred at this temperature
for 15 minutes and then at RT for 10 minutes. Excess of bromine was
eliminated with sodium metabisulphite and the reaction brought to
pH 8 by addition of saturated solution of Na.sub.2CO.sub.3. The
organic solvents were evaporated under reduced pressure, to give a
solid that was filtered and used for the following reaction without
further purification.
[0259] Yield 82%.
STEP D:
1-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol
(ST3829)
[0260] To the solution of
1-(6-amino-8-bromo-9-methyl-9H-purin-2-yl)-butan-1-ol (1.4 g, 4.56
mmol) in anhydrous DMF (20 ml) were added C.sub.sCO.sub.3 (5.9 g,
18.24 mmol) and then 1H-1,2,3-triazole (1.2 g, 1.0 m1,18.24 mmol).
The mixture was stirred overnight at 90.degree. C. The solvent was
evaporated under reduced pressure to give a residue that was
purified by flash chromatography (DCM/MeOH: 93/7).
[0261] Yield 30%.
[0262] .sup.1H NMR (DMSO-d.sub.6) .delta.: 0.92 (t, 3H, J=7.18),
1.40 (q, 2H, J=8.2), 1.75 (m, 2H), 3.86 (s, 3H), 4.50 (m, 1H), 4.88
(d, 1H), 7.58 (bs, 1H), 8.37 (s, 2H).
[0263] .sup.13C NMR (DMSO-d.sub.6) .delta.: 14.94, 19.37, 31.34,
39.88, 74.06, 115.90, 138.63, 142.27, 151.42, 156.64, 167.72.
[0264] MS (ESI+): 289(M+H).sup.+
Example 6
1-(6-Amino-9-methyl-8-[1,2,3]triazol-2-14-9H-purin-2-1/1)-butan-1-one
ST4208
[0265] MnO.sub.2 (439mg, 5.04 mmol) was added to a solution of
1-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)butan-1-ol
(51mg, 0.2mmol) in DCM (4 ml) at RT. The resulting heterogeneous
solution was stirred overnight. After filtration over a celite pad,
the solvent was removed under reduced pressure to afford the
desired product as a white powder.
[0266] Yield 40%.
[0267] .sup.1H NMR (DMSO-d.sub.6) .delta.: 8.4 (s, 2H), 7.7 (bs,
2H), 3.9 (s, 3H), 3.14 (t, 2H), 1.66 (m, 2H), 0.95 (t, 3H)
[0268] ESI-MS (m/z): 287.1(M+H).sup.+
Example 7
4-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl
-9H-purin-2-yl)-butan-2-one ST4206
[0269] Molecular sieves 4 .ANG.(100 mg) and PCC (59 mg, 0.273 mmol)
at 0.degree. C. were added to a solution of
4-(6-amino-9-methyl-8[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-ol
(25 mg, 0.086 mmol) in DCM (1.2 ml). The mixture was stirred at RT
for 1 h and then diluted with Et.sub.2O at 0.degree. C. and stirred
for 30 minutes. The resulting suspension was filtered through a
celite pad. The filtrate was concentrated in vacuo and the residue
was purified by silica gel column chromatography (DCM to DCM/MeOH:
95/5) to afford a white powder.
[0270] Yield 37%.
[0271] .sup.1H NMR (CD.sub.3CN) .delta.: 8.1 (s, 2H), 5.9 (bs, 2H),
3.8 (s, 3H), 3.07 (t, 2H), 2.9 (t, 2H), 2.2 (s, 3H).
[0272] ESI-MS (m/z): 287.1 (M+H).sup.+
[0273] In alternative,
4-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-one
can be prepared from an advanced intermediate obtained by a process
involving Method B as above mentioned and as described
underneath.
Preparation 1
4-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H
-purin-2-yl)-butan-2-one (ST4206)
STEP A:
Dibenzyl-{9-methyl-2-[2-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-ethyl]--
9H-purin-6-yl}-amine
[0274] i) 1,2-dibromoethane (770 .mu.l, 8.9 mmol) was added to a
suspension of Mg (3.1 g, 127.5 mmol) in THF (75 ml) in inert
atmosphere (Ar). Then, a solution of
2-(2-bromoethyl)-2,5,5-trimethyl-1,3-dioxane (8.0 ml, 42.5 mmol)
and 1,2-dibromoethane (3.08 ml, 36 mmol) in THF (75 ml) was added,
and after the exothermic reaction was completed, the resulting
reaction mixture was heated to 50.degree. C. for 1 h.
[0275] ii) Fe(acac).sub.3 (315 mg, 0.89 mmol) was added to a
solution of dibenzyl-(2-chloro-9-methyl-9H-purin-6-yl)-amine (3.24
g, 8.9 mmol) in THF (115 ml) and NMP (28. 5 ml) and the resulting
reaction mixture was stirred at RT for 30 min. 140 ml of the
freshly prepared reagent obtained from STEP A (i) were added to the
reaction mixture and the stirring was maintained for 1 h. The
solvent was removed under reduced pressure, and the crude reaction
mixture was poured into water and extracted by means of AcOEt. The
combined organic phases were washed with brine and dried with
Na..sub.2SO.sub.4. After removal of the solvent under reduced
pressure, the desired adduct was obtained quantitatively as a brown
oil.
[0276] .sup.1H NMR (CDCl.sub.3) .delta.: 0.85 (s, 3H), 1.00 (s,
3H), 1.30 (s, 3H), 1.89-2.00 (m, 2H), 2.85-2.91 (m, 2H), 3.47-3.61
(m, 4H), 3.80 (s, 3H), 4.91(brs, 2H), 5.40(brs, 2H), 7.2-7.4 (m,
10H), 7.66 (s, 1H).
[0277] ESI-MS (m/z): 486 (M+H).sup.+
STEP B: Dibenzyl-{8-bromo-9-methyl-2-[2-(2,5,5-trimethyl- 8
1,31]dioxan-2-yl)-ethyl]-9H-purin-6-yl}amine
[0278] Bromine (0.89 ml, 17.5 mmol) was added dropwise at 0.degree.
C. to a solution of
dibenzyl-{9-methyl-2-[2-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-ethyl]-9H-puri-
n-6-yl}amine (1.7 g, 3.50 mmol) in 20 ml of a mixture of MeOH/THF
(1/1) and acetate buffer pH=4 (10 ml). The latter was obtained
dissolving 4 g of sodium acetate in 100 ml of water and by
adjusting to pH 4 through addition of glacial acetic acid. The
reaction was stirred at RT for two hours. Excess of bromine was
quenched by addition of sodium metabisulphite and the reaction was
brought to pH 8 by addition of a saturated solution of
Na.sub.2CO.sub.3. The organic solvents were evaporated under
reduced pressure, to give a solid that was filtered and used
without any further purification in the next step.
[0279] .sup.1H NMR (CDCl.sub.3) .delta.: 0.85 (s, 3H), 1.00 (s,
3H), 1.30 (s, 3H), 1.89-2.00 (m, 2H), 2.82-2.89 (m, 2H), 3.47-3.61
(m, 4H), 3.75 (s, 3H), 4.91(bs, 2H), 5.40(bs, 2H), 7.20-7.40 (m,
10H).
[0280] ESI-MS (m/z): 564-566 (M+H).sup.+
[0281] STEP C:
Dibenzyl-{9-methyl-8-[1,2,3]triazol-2-yl-2-[2-(2,5,5-trimethyl-[1,3]dioxa-
n-2-yl)-ethyl]-9H-purin-6-yl}-amine
[0282] To a solution of
dibenzyl-{8-bromo-9-methyl-2-[2-(2,5,5-trimethyl-[1,3]dioxan-2-yl)-ethyl]-
-9H-purin-6-yl}amine (1.9 g, 3.50 mmol) in anhydrous DMF (20 ml)
were added K.sub.2CO.sub.3 (0.72 g, 5.2 mmol) followed by
1H-1,2,3-triazole (362 mg, 5.2 mmol). The mixture was stirred
overnight at 100.degree. C. The solvent was evaporated under
reduced pressure to give a residue that was purified by flash
chromatography (DCM/MeOH: 93/7).
[0283] Yield 30%.
[0284] .sup.1H NMR (CDCl3) .delta.: 0.85 (s, 3H), 1.00 (s, 3H),
1.30 (s, 3H), 1.89-2.00 (m, 2H), 2.79-2.83 (m, 2H), 3.47-3.61 (m,
4H), 3.90 (s, 3H), 4.91(brs, 2H), 5.40 (bs, 2H), 7.2-7.4 (m, 10H),
8.00 (s, 21-1).
[0285] MS(ESI) m/e: 553 (M+H).sup.+
STEP D:
4-(6-Amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-o-
ne (ST4206)
[0286] The intermediate obtained form STEP C, was deprotected using
standard TfOH conditions, which after chromatography on silica gel
allowed the obtention of the desired adduct quantitatively.
[0287] .sup.1H NMR (CD3CN) .delta.: 8.10 (s, 2H), 5.90 (bs, 2H),
3.80 (s, 3H), 3.07 (t, 2H), 2.90 (t, 2H), 2.20 (s, 3H).
[0288] ESI-MS (m/z): 287 (M+H).sup.+
[0289] In alternative,
4-(6-amino-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-2-yl)-butan-2-one
can be prepared from an advanced intermediate obtained by a process
involving Method E as above mentioned and as described
underneath.
Preparation 2
[0290] Hermann catalyst (8 mg, 0.008 mmol, 0.08 eq), Bu.sub.4NBr (8
mg, 0.025 mmol, 0.25 eq), NaOAc (9 mg, 0.11 mmol, 1.1 eq) and
3-buten-2-ol (13.mu.l, 0.15 mmol, 1.5 eq) were added to a solution
of
(2-chloro-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-yl)-bis-(4-methoxy-be-
nzyl)-amine (49 mg, 0.10 mmol) in NMP (1 ml). The resulting
reaction mixture was heated to 100.degree. C. for 16 h and further
Hermann catalyst, Bu.sub.4NBr, and NaOAc were added in the same
proportions together with further 3 eq of 3-buten-2-ol. The
stirring was continued for 22 h at 140.degree. C. before cooling to
RT. The resulting crude suspension was diluted with AcOEt and the
solid was filtered off. The organic phase was washed with H.sub.2O
and then dried over Na.sub.2SO.sub.4. Removal of the solvent under
vacuo and purification through preparative thin layer
chromatography allowed the obtention as a white solid of the
desired
4-{6-[bis-(4-methoxy-benzyl)-amino]-9-methyl-8-[1,2,3]triazol-2-yl-9H-pur-
in-2-yl}-butan-2-one.
[0291] Yield 42%.
[0292] .sup.1H NMR (CDCl.sub.3) .delta.: 2.12 (s, 3H), 2.94 (t,
2H), 3.16 (t, 2H), 3.78 (s, 6H), 3.94 (s, 3H), 4.85 (bs, 2H),
5.39(bs, 2H), 6.82 (d, 4H), 7.18 (d, 4H), 7.94 (s, 2H).
Biology
[0293] The compounds of the present invention were tested in a
competition binding assay for their ability to inhibit A.sub.2a
receptor.
Example 8
A.sub.2a Receptor Inhibition
[0294] Method
[0295] HEK293 Cell Culture and Membrane Preparation
[0296] HEK293 cells, stably expressing the human adenosine
A.sub.2a, receptor gene (PerkinElmer, Boston, Mass., USA, cat.
RBHA2AC), were grown in Falcon flasks in DMEM (Cambrex, Verviers,
Belgium) supplemented with 10% FBS (Cambrex), 1 mmol/l sodium
pyruvate (Sigma-Aldrich, Saint Louis, Mo., USA), 0.4 mg/ml G418
(Sigma-Aldrich) at 37.degree. C. in a 5% CO.sub.2 atmosphere. For
radioligand binding experiments, the cells were collected at 80% of
confluence, in 5 mmol/l Tris-HCl (Sigma-Aldrich), pH 7.4,
containing 2 mmol/l EDTA, counted, washed in PBS (Cambrex),
resuspended in incubation buffer A containing 50 mmol/l Tris-HCl,
pH 7.4,10 mmol/l MgCl.sub.2 (Sigma-Aldrich) and homogenized using
an Ultra Turrax T25. The membranes were centrifuged and homogenized
once again and the final pellet was stored at -80.degree. C. until
use. Prior to the competition binding assay, the pellet was
resuspended in buffer A at the desired protein concentration and
membrane suspension was incubated with 2 U/ml adenosine deaminase
(ADA, Sigma-Aldrich) for 30 min at 37 .degree. C. to remove
endogenous adenosine.
Protein Concentration and Competition Binding Assay
[0297] The protein concentration of membrane suspension was
determined using the Bradford method (Pierce, Rockford, Ill., USA)
with bovine albumin as standard. Competition binding experiments
were performed by incubating membranes (5-10 .mu.g of
protein/sample) with a single concentration of the A.sub.2a
antagonist [.sup.3H]ZM241385 (Biotrend, Cologne, Germany) (2
nmol/l), in the presence of various concentrations (ranging from
10.sup.-5 to 10.sup.-11 mol/l) of test and reference compounds in
96-well filter plates (MultiScreen system, cat. MAFBNOB10,
Millipore, Billerica, Mass., USA) for one h at 4 .degree. C. in a
total volume of 200.mu.l/well of appropriate buffer (50 mmol/l
Tris-HCl, pH 7.4, 10 mmol/l MgCl.sub.2). Nonspecific binding was
determined in the presence of 10 .mu.mol/l cold ZM241385 (Tocris,
Ellisville, Mo., USA). At the end of incubation, bound and free
radioligands were separated by filtering the 96-well filter plates
using a Millipore filtration apparatus (MultiScreenHTS vacuum
manifold). Filter plates were then washed several times with
ice-cold buffer (50 mmol/l Tris-HCl, pH 7.4) and filter-bound
radioactivity measured using a MicroBeta counter (PerkinElmer)
after addition of 30 .mu.l/well of OptiPhase SuperMix scintillation
cocktail (PerkinElmer). Four experiments were performed in
triplicate by JANUS.RTM. automated workstation (Perkin Elmer).
[0298] Data were analyzed by nonlinear regression analysis with
GraphPad PRISM commercial software and expressed as IC.sub.50,
defined as the concentration of compounds that inhibits 50% of
[.sup.3H]ZM241385 binding. Inhibitory binding constant (Ki) values
were calculated from IC.sub.50 values according to the Cheng and
Prusoff equation Ki=IC.sub.50/(1+[C]/K.sub.d), where [C] is the
concentration of the radioligand and K.sub.d its dissociation
constant.
Results
[0299] All tested compounds proved to be highly active in binding
A2A receptor assay (table 1).
TABLE-US-00001 TABLE 1 A.sub.2A Examples Ki nM 1 53 2 8 3 19 4 8 5
22 6 19 7 12
Example 9
[0300] A1 receptor inhibition
[0301] Method
[0302] Competition binding experiments have been performed
incubating membranes from CHO-K1 cells stably transfected with the
human adenosine Al receptor (cat. ES-010-M400UA, Perkin Elmer,
Boston, Mass., USA) (5-10 .mu.g of protein/sample) with a single
concentration of [3H]DPCPX (1.7 nmol/l) (Perkin Elmer), in the
presence of various concentrations (ranging from 10.sup.-5 to 10
.sup.-10 M) of cold DPCPX, ST4206 and ST4208 in 96-well filter
plates (MultiScreen system, cat #MAFBNOB10, Millipore, Billerica,
Mass., USA) for 60 min at 25.degree. C. in a total volume of 200
.mu.L/well of 25 mmol/l Hepes, 5 mmol/l MgCl.sub.2, 1 mmol/l
CaCl.sub.2, 100 mmol/L NaCl, pH 7.4 (all from Sigma-Aldrich).
Non-specific binding has been determined in the presence of 250
.mu.mol/l of cold DPCPX (8-cyclopentyl-1,3-dipropylxanthine,
Sigma-Aldrich). At the end of incubation, bound and free
radioligands have been separated by filtering the 96-well filter
plates using a Millipore filtration apparatus (MultiscreenHTS
vacuum manifold). Filter plates have been washed several times with
ice-cold buffer (50 mmol/l Tris-HCl, pH 7.4) and filter-bound
radioactivity measured using a MicroBeta counter (PerkinElmer)
after addition of 30 .mu.L/well of OptiPhase SuperMix scintillation
cocktail (PerkinElmer).
[0303] Data have been analyzed using nonlinear regression with
GraphPad PRISM commercial software. Data will be expressed as test
compound concentration causing a half maximal inhibition of control
values (IC.sub.50). Inhibitory binding constant (Ki) values will be
calculated from IC.sub.50 values, according to the Cheng and
Prusoff equation K.sub.i=IC.sub.50/(1+[C]/K.sub.d), where [C] is
the concentration of the radioligand and K.sub.d its dissociation
constant.
Results
[0304] Tested compounds bound A.sub.1 adenosine receptors with the
Ki values reported in Table 2.
TABLE-US-00002 TABLE 2 A.sub.1 Examples Ki nM 1 51 2 27 5 120 6 216
7 197
Example 10
[0305] cAMP Inhibition
[0306] The compounds of the present invention were tested to assess
their capacity to inhibit cAMP accumulation induced by the A.sub.2A
agonist 5'-N-ethylcarboxamidoadenosine (NECA).
Methods
[0307] cAMP quantitative determination was performed with an enzyme
immunoassay system (cat. RPN2255, Amersham Biosciences) according
to manufacturer's instructions. HEK 293 cells, stably expressing
the human adenosine A.sub.2a, receptor gene (PerkinElmer, Boston,
Mass., USA, cat. RBHA2AC), were grown in Falcon flasks in DMEM
(Cambrex, Verviers, Belgium) supplemented with 10% FBS (Cambrex), 1
mmol/1 sodium pyruvate (Sigma-Aldrich, St. Louis, Mo., USA), and
0.4 mg/ml G418 (Sigma-Aldrich) at 37.degree. C. in a 5% CO.sub.2
atmosphere. Cells were plated on 96-well dishes at a concentration
of 10.sup.3 cells/well 48 hours before test compound exposure.
Before cell stimulation with the compounds, cells were treated for
10 min at 37.degree. C. with 0.5 mmol/l of the phosphodiesterase
inhibitor Ro 20-1724 (Sigma-Aldrich) and with 2 U/ml of adenosine
deaminase (ADA, Sigma-Aldrich). Medium was then changed with fresh
medium containing scalar concentrations of test compounds
(10.sup.-10-10.sup.-4 mol/l) at 37.degree. C. and, after 10 min,
100 nmol/l NECA was added cAMP was extracted 20 min after and
quantified.
[0308] Data were analyzed by nonlinear regression analysis with
GraphPad PRISM commercial software. Test compound concentrations
causing a half maximal inhibition of control values (IC.sub.50
calculated by GraphPad Prism software) was reported (mean.+-.SEM of
four independent experiments).
Results
[0309] All compounds resulted efficacious at inhibiting
agonist-induced cAMP accumulation (table 3) and behaved as expected
for A.sub.2a receptor antagonists.
TABLE-US-00003 TABLE 3 cAMP Examples IC.sub.50 .mu.M 1 2.12 2 0.45
3 0.26 4 0.42 5 2.32 6 2.92 7 0.99
Example 11
[0310] In order to evaluate the selectivity profile of the
compounds of the present invention, three of them (ST3829, ST3932
and ST4023) were also characterized for their affinity toward a
battery of 51 different receptors. The majority of the 51 assays
were human recombinant receptors of the following types: adenosine,
adrenergic, cannabinoid, dopamine, GABA, histamine, melatonin,
muscarinic, prostanoid and serotonin receptors belonging to non
peptide receptors family; angiotensin-II, bradychinin, chemokines,
cholecistokinin, endothelin, galanin, melacortin, neurokinin,
neuropeptide Y, neurotensin, opioid and opioid like, somatostatin,
vasoactive intestinal peptide and vasopressin receptors belonging
to peptide receptors family; Ca.sup.2+ channel, K.sup.+ channel and
Nachannel belonging to the ion channel family and dopamine,
norepinephrine and serotonin belonging to the amine transporters
receptors family. These three compounds were tested at a
concentration of 10.mu.M. Interestingly, none of them demonstrated
any substantial affinity toward any of the above-mentioned
receptors.
Example 12
Haloperidol-Induced Catalepsy Mice Model
[0311] ST3829, ST3932 and ST4023 were tested to assess their
capacity to antagonize haloperidol-induced catalepsy in mice.
Methods
[0312] Haloperidol (2 mg/kg) was injected i.p. to CD1 mice 2.5 h
before oral administration of ST3932 or ST4206. The latter were
administered at doses of 10, 20 or 40 mg/kg.
[0313] Then, each CD1 mouse was gently placed by its forepaws on a
wire at a height of 4.5 cm. Catalepsy was measured as the time
(expressed in seconds) necessary for the animal to step down with
at least one forepaw, with an end point of 60 seconds, time after
which the mouse was gently removed from the wire. Then, catalepsy
was scored every 60 min for seven h.
Data Evaluation
[0314] All data were expressed both as individual and mean values,
plus or minus standard error (Mean.+-.SEM) of catalepsy time in
seconds. Statistical analysis was performed using sigma stat
program. After calculation of AUC throughout 7 hours, the one-way
ANOVA followed by Dunnett's test were used. Basal time was not
considered statistically because this time-point was only used to
check that catalepsy was successfully induced in all animals.
Results
[0315] Both ST3932 and ST4206 significantly antagonized
haloperidol-induced catalepsy in a dose-dependent manner (FIGS. 1
and 2).
Example 13
Enhancement of L-DOPA Antiparkinsonian Activity
[0316] Rats (Sprague Dawley) under chloral hydrate (400 mg/kg)
anaesthesia were placed in a Kopf stereotaxic apparatus. Through a
stainless steel cannula, 6-OHDA was injected at a rate of 1
.mu.l/min into the left medial forebrain bundle at coordinates
A=-2.2, L=+1.5 and V=-7.8, according to the Pellegrino atlas. All
rats, including shams, were treated with desipramine (10 mg/kg) 10
min before anaesthesia to prevent damage to noradrenergic
neurons.
[0317] Two weeks after the 6-OHDA injection, all animals were
tested for their contra lateral rotation capacity in response to 30
mg/kg i.p. benserazide followed by 50 mg/kg i.p. of L-Dopa 30 min
later. Rats not showing at least 200 contra lateral rotations
within the 3 h testing period were eliminated from the study. One
week after this test, selected animals were randomized to be
enrolled in three studies. Each study involved seven groups of
eight animals.
[0318] Tested compounds (ST3829, ST3932 and ST4206) were dissolved
in a solution containing 10% sucrose and 0.3% Tween 80 in sterile
water in order to obtain three different dosage forms (i.e., 10, 20
and 40 mg/kg).
TABLE-US-00004 Group 1 Tested compound 10 mg/kg Group 2 Tested
compound 20 mg/kg Group 3 Tested compound 40 mg/kg Group 4 6 mg
benserazide + 3 mg L-DOPA Group 5 Tested compound 10 mg/kg and 6 mg
benserazide + 3 mg L-DOPA Group 6 Tested compound 20 mg/kg and 6 mg
benserazide + 3 mg L-DOPA Group 7 Tested compound 40 mg/kg and 6 mg
benserazide + 3 mg L-DOPA
[0319] In groups 5, 6 and 7 benserazide was administered first,
followed by the tested compound 25 min after and finally by L-DOPA
5 min later.
Results
[0320] In the 6-OHDA rat model of Parkinson's disease, adenosine
A2a receptor antagonists increase turning behaviour induced by
L-Dopa showing antiparkinsonian effects. In this study it was shown
that ST3932 and ST4206, administered to rats with a threshold dose
of L-Dopa, increased the contralateral turning behaviour induced by
L-Dopa displaying a marked antiparkinsonian activity.
* * * * *